Literature DB >> 24368188

Interferon response factor 3 is crucial to poly-I:C induced NK cell activity and control of B16 melanoma growth.

Tyler C Moore1, Phyllis M Kumm2, Deborah M Brown3, Thomas M Petro4.   

Abstract

Interferon Response Factor 3 (IRF3) induces several NK-cell activating factors, is activated by poly-I:C, an experimental cancer therapeutic, but is suppressed during many viral infections. IRF3 Knockout (KO) mice exhibited enhanced B16 melanoma growth, impaired intratumoral NK cell infiltration, but not an impaired poly-I:C therapeutic effect due to direct suppression of B16 growth. IRF3 was responsible for poly-I:C decrease in TIM-3 expression by intratumoral dendritic cells, induction of NK-cell Granzyme B and IFN-γ, and induction of macrophage IL-12, IL-15, IL-6, and IRF3-dependent NK-activating molecule (INAM). Thus, IRF3 is a key factor controlling melanoma growth through NK-cell activities, especially during poly-I:C therapy.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; IRF3; Melanoma; NK-cells; Poly-I:C

Mesh:

Substances:

Year:  2013        PMID: 24368188      PMCID: PMC3963264          DOI: 10.1016/j.canlet.2013.12.022

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  50 in total

1.  Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12.

Authors:  T Kodama; K Takeda; O Shimozato; Y Hayakawa; M Atsuta; K Kobayashi; M Ito; H Yagita; K Okumura
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

2.  A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.

Authors:  B Naume; M Gately; T Espevik
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

Review 3.  Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis.

Authors:  S Shresta; J W Heusel; D M Macivor; R L Wesselschmidt; J H Russell; T J Ley
Journal:  Immunol Rev       Date:  1995-08       Impact factor: 12.988

Review 4.  Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation.

Authors:  G Trinchieri; M Wysocka; A D'Andrea; M Rengaraju; M Aste-Amezaga; M Kubin; N M Valiante; J Chehimi
Journal:  Prog Growth Factor Res       Date:  1992

5.  Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo.

Authors:  M G Wathelet; C H Lin; B S Parekh; L V Ronco; P M Howley; T Maniatis
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

6.  Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis.

Authors:  D D Taub; T J Sayers; C R Carter; J R Ortaldo
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

7.  C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins.

Authors:  A A Maghazachi; A al-Aoukaty; T J Schall
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

8.  Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization.

Authors:  L Shi; S Mai; S Israels; K Browne; J A Trapani; A H Greenberg
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

9.  Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase.

Authors:  M C Nakamura; E C Niemi; M J Fisher; L D Shultz; W E Seaman; J C Ryan
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

10.  Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.

Authors:  R Lupetti; P Pisarra; A Verrecchia; C Farina; G Nicolini; A Anichini; C Bordignon; M Sensi; G Parmiani; C Traversari
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  7 in total

1.  Significant role for IRF3 in both T cell and APC effector functions during T cell responses.

Authors:  Zacharey Guinn; Anna T Lampe; Deborah M Brown; Thomas M Petro
Journal:  Cell Immunol       Date:  2016-09-04       Impact factor: 4.868

2.  Interferon regulatory factor 3 plays a role in macrophage responses to interferon-γ.

Authors:  Zachary P Guinn; Thomas M Petro
Journal:  Immunobiology       Date:  2019-05-02       Impact factor: 3.144

3.  Activation of IRF3 contributes to IFN-γ and ISG54 expression during the immune responses to B16F10 tumor growth.

Authors:  Zachary Guinn; Deborah M Brown; Thomas M Petro
Journal:  Int Immunopharmacol       Date:  2017-06-23       Impact factor: 4.932

4.  The cryo-thermal therapy eradicated melanoma in mice by eliciting CD4+ T-cell-mediated antitumor memory immune response.

Authors:  Kun He; Ping Liu; Lisa X Xu
Journal:  Cell Death Dis       Date:  2017-03-23       Impact factor: 8.469

5.  Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity.

Authors:  Kun He; Shengguo Jia; Yue Lou; Ping Liu; Lisa X Xu
Journal:  Cell Death Dis       Date:  2019-03-04       Impact factor: 8.469

6.  PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.

Authors:  Hiroshi Nakano; Motonobu Saito; Shotaro Nakajima; Katsuharu Saito; Yuko Nakayama; Koji Kase; Leo Yamada; Yasuyuki Kanke; Hiroyuki Hanayama; Hisashi Onozawa; Hirokazu Okayama; Shotaro Fujita; Wataru Sakamoto; Zenichiro Saze; Tomoyuki Momma; Kosaku Mimura; Shinji Ohki; Akiteru Goto; Koji Kono
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

7.  TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.

Authors:  Martina Damo; David S Wilson; Eleonora Simeoni; Jeffrey A Hubbell
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.